Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Vaccine|February 11, 2014
Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled studyRoman Chlibek, Jan Smetana, Karlis Pauksens, et al.
The Pediatric Infectious Disease Journal|July 10, 2012
Safety of a 2-dose regimen of a combined measles, mumps, rubella and varicella live vaccine manufactured with recombinant human albuminGabriela Rüger, Giovanni Gabutti, Hans Rümke, et al.
The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|April 24, 2010
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girlsDoris M Rivera Medina, Alejandra Valencia, Alet de Velasquez, et al.
Human Vaccines & Immunotherapeutics|February 21, 2018
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adultsTino F Schwarz, Stephanie Volpe, Gregory Catteau, et al.
Pediatrics|May 16, 2007
Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live)Henry H Bernstein, Karen Eves, Kristy Campbell, et al.
Vaccine|August 27, 2019
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trialTom M A Wilkinson, Stuart Schembri, Christopher Brightling, et al.
Vaccine|November 28, 2017
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and 4vHPV vaccine administered according to two- or three-dose schedules in girls aged 9-14 years: Results to month 36 from a randomized trialTing Fan Leung, Anthony Pak-Yin Liu, Fong Seng Lim, et al.
Vaccine|April 15, 2008
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trialHans C Rümke, José-María Bayas, José-Ramón de Juanes, et al.
Human Vaccines & Immunotherapeutics|June 11, 2015
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trialTing Fan Leung, Anthony Pak-Yin Liu, Fong Seng Lim, et al.
Eclinicalmedicine|July 9, 2025
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complicationsAna Strezova, Javier Díez Domingo, Anthony L Cunningham, et al.
Pageof 8